Novel Mouse Model for research and study of therapeutic treatments in Psoriasis
Researchers at the University of Dundee have developed the first transgenic mouse model which induces the expression of the PPARδ gene, which is known to be expressed in human psoriatic skin but is not expressed in mouse skin.
In the model, the PPARδ gene is activated by the administration of a synthetic ligand. Researchers developed the model to demonstrate many clinical and histological effects of Psoriasis, including dependance on Th17 lymphocytes within 21 days.
The skin phenotype has 100% penetrance, is
responsive to Th17 - targeted therapy, and fully reversible, furthermore, transcriptional dysregulation in this model largely overlaps with that seen with Psoriasis.
The model does not require human skin grafting or implantations, therefore, the ability to screen is improved and the process of operating a model is simplified.
This model presents advantages over existing models and a robust complimentary tool for research in inflammatory skin conditions.Key Benefits
- Suitable for screening potential therapeutic treatments
- Removes need for skin grafts
- Expression within 21 days
- Simplification technology
- Demonstrates major hallmarks of Psoriasis
- Patent application filed
Applications
- Psoriasis
- Inflammation
- Skin Research
- Dermatology
IP Status
A patent application has been filed.
If you would like further information about
this opportunity please fill out the form below. Your enquiry will
be passed on to the relevant University who will respond to you directly.
